CONMED Corporation

AI-generated fair value estimate for this company.

Method: 10-year unlevered FCF DCF: $134.46M TTM free cash flow base; 5% FCF growth years 1-5 (medical device market growth plus margin recovery from recent one-time items that depressed FY net income); 3.5% years 6-10; 9% discount rate; 2.5% terminal growth; ~$796.9M net debt; 29.95M shares outstanding.

Reasoning: CONMED's free cash flow generation remained solid even as reported net income fell sharply on what appear to be one-time charges, so the DCF is anchored to the more stable free cash flow base; the discount rate and growth path reflect typical mid-cap medical device sector characteristics.